Exposure to particulate matter: Direct and indirect role in the COVID-19 pandemic미립자 물질에 대한 노출: COVID-19 전염병에서 직간접적인 역할Article Published on 2022-04-152022-09-11 Journal: Environmental research [Category] COVID19(2023년), SARS, 치료기술, [키워드] ACE-2 addition aerosol Aerosols Air pollution anthropogenic Clinical severity COVID-19 COVID-19 pandemic demonstrated develop Direct effective evaluate explained exposure to expression Factor favor hosts Hypothesis Indicator Inflammatory response matter Natural environment outbreak oxidative stress Particle Particulate Particulate matter respiratory cell respiratory cells Respiratory system SARS-CoV-2 SARS-CoV-2 RNA Spread suspended particles Transmission vector viability viral infection Viral load virus [DOI] 10.1016/j.envres.2021.112261 PMC 바로가기 [Article Type] Article
CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial CellsCFTR 조절은 인간 기관지 상피 세포에서 SARS-CoV-2 감염을 감소시킵니다Article Published on 2022-04-152022-09-11 Journal: Cells [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] ACE-2 analyzed bronchial bronchial cell bronchial epithelial cell bronchial epithelial cells Cell cell lines cells CFTR CFTR inhibitor clone Combination correction COVID-19 cystic fibrosis detectable elicited epithelial cell epithelial cell line epithelial cells evaluated Evidence expressing expression fibrosis flow cytometry Human human bronchial epithelial cells human bronchial epithelial cells. immortalized increased risk Infection inhibited inhibitor involved IOWH-032 Post-infection primary cell primary cells primary human bronchial epithelial cells provide real-time RT-PCR reduced Regulation Replication restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication SARS-CoV-2 viral particles SARS-CoV-2 virus severe symptom severe symptoms Spread subjects supernatant Therapeutic strategies therapeutic strategy Viral Viral load viral replication was reduced were infected wild-type [DOI] 10.3390/cells11081347 PMC 바로가기 [Article Type] Article
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19코비드-19를 가진 고위험, 입원하지 않은 성인을 위한 경구 NirmatrelvirClinical Trial Published on 2022-04-142022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted Administered adverse event adverse events Analysis assigned conducted Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 death deaths diarrhea double-blind drug dysgeusia enhancer evaluated Final final analysis high risk Hospitalization in vitro incidence inhibitor initiated interim analysis log M pro mean difference milliliter modified intention-to treat modified intention-to-treat Nirmatrelvir occurred onset of symptoms oral Patient patients patients treated Pfizer pharmacokinetic Placebo placebo group progression protease randomization randomized, controlled trial receive Relative risk risk risk reduction Ritonavir Serious Adverse Events severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 symptom onset symptomatic symptomatic COVID-19 the placebo group Treatment treatment period two group two groups Viral load [DOI] 10.1056/NEJMoa2118542 PMC 바로가기 [Article Type] Clinical Trial
Increased close proximity airborne transmission of the SARS-CoV-2 Delta variantSARS-CoV-2 Delta 변종의 근거리 공중 전파 증가Article Published on 2022-04-102022-09-11 Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 변종, [키워드] Airborne transmission breathing cause close contact Contact coughing delta variant dose-response model hosts Increased Infection occupational health overdispersion performed Reproduction number risk SARS-CoV-2 SARS-CoV-2 Delta variant social contact the SARS-CoV-2 Transmission Viral load wild-type SARS-CoV-2 [DOI] 10.1016/j.scitotenv.2021.151499 PMC 바로가기 [Article Type] Article
A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant재조합 소단위 백신은 SARS-CoV-2 P.1(감마) 변이체에 대한 원숭이에서 강력하고 광범위하게 중화되며 내구성 있는 항체 반응을 유도합니다Article Published on 2022-04-082022-09-11 Journal: ACS Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anamnestic response Antigen B.1.351 B.1.617 Beta boost breadth cause circulating Concentration coronavirus CoVaccine HT cynomolgus macaques delayed challenge disease dose dosed effective Efficacy elevated evaluated Final Gamma Heterologous IgG Immunity immunization immunized immunogenic induce Infection information isolates liquid Lower respiratory tract Lung pathology lyophilized macaque macaques moderate moderate to severe mRNA natural infection Neutralizing antibodies neutralizing antibody Neutralizing antibody response P.1 pandemic potent Prevent Protective protective immunity Protein recombinant reduce Reinfection required respiratory response restored robust SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe disease significantly specific neutralizing antibodies subunit subunit protein vaccine Subunit vaccine the SARS-CoV-2 upper and lower respiratory tract Vaccine vaccine immunity variants of concern Viral Viral load viral loads VoC VOCs [DOI] 10.1021/acsinfecdis.1c00600 PMC 바로가기 [Article Type] Article
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 Research Published on 2022-04-082022-10-05 Journal: Nature Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome addition aerosol benefit contribute coronavirus defined Delta determine droplet expelled FIVE Guidance high infectiousness in vitro individual individuals infected individual infected with SARS-CoV-2 mechanism omicron public health public health measures qRT–PCR quantified reduced risk RNA SARS-CoV-2 second dose severe disease significantly symptomatic day transmissibility of SARS-CoV-2 Transmission vaccinated individual vaccination Vaccine variant Viral load [DOI] 10.1038/s41591-022-01816-0 [Article Type] Research
Does a humoral correlate of protection exist for SARS-CoV-2? A systematic reviewSARS-CoV-2에 대한 체액 보호 상관관계가 있습니까? 체계적인 검토Article Published on 2022-04-082022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Alpha anti-S antibody antibody levels B.1.1.7 binding antibody Biosis Breakthrough infection contribute convalescent correlation COVID-19 decrease Evidence examined global health humoral Humoral immunity immune component immunological incidence individual level Infection levels of antibodies marker Measures NIH occur pandemic performed Policy Quantitative Re-infection reported risk risk of infection SARS-CoV-2 searched systematic review the mean variant variants variants of concern Viral Viral load [DOI] 10.1371/journal.pone.0266852 PMC 바로가기 [Article Type] Article
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment코로나19 치료를 위한 몰누피라비르의 항바이러스 효능Article Published on 2022-04-062022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 95% CI active against Administered Antiviral antiviral drug antiviral drugs antiviral efficacy antiviral efficacy. coronavirus COVID-19 COVID-19 pandemic exacerbated expected global pandemic Government granular growth infected cell infected cells infectiousness inhibit Intervention mathematical molnupiravir per day pharmaceutical Pharmaceutical interventions public health reduce Replication risk SARS-CoV-2 SARS-CoV-2 variants Seven treated Viral load virus [DOI] 10.3390/v14040763 PMC 바로가기 [Article Type] Article
In Vitro SARS-CoV-2 Infection of Microvascular Endothelial Cells: Effect on Pro-Inflammatory Cytokine and Chemokine Release미세혈관 내피 세포의 시험관 내 SARS-CoV-2 감염: 염증성 사이토카인 및 케모카인 방출에 대한 영향Article Published on 2022-04-062022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 치료기술, [키워드] ACE2 receptor Activation Analysis chemokine contribute coronavirus disease Coronavirus disease 2019 cytokine release Cytokines cytoplasm days post-infection dysfunction Effect electron ELISA endothelial Endothelial cell evaluated expressed expression Human Human Microvascular Endothelial Cells (HMEC-1) IFN-α IL-6 IL-6 level IL-6 levels IL-8 in vitro Inflammatory mediators mRNA mRNA expression pandemic pro-inflammatory cytokine pro-inflammatory cytokines pro-inflammatory mediators Release RT-PCR SARS-CoV-2 SARS-COV-2 infection significantly higher significantly lower supernatant supernatants susceptible TEM These data thrombotic Thrombotic events tissue Tissue Factor TNF-α transmission electron microscopy uninfected viral amplification Viral load virion virions western blot Western blot analysis [DOI] 10.3390/ijms23074063 PMC 바로가기 [Article Type] Article
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques캡시드 바이러스 유사 입자 기반 SARS-CoV-2 백신은 높은 수준의 항체를 유도하고 붉은털 원숭이를 보호합니다Article Published on 2022-04-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antibody titers binding binding and neutralizing antibodies broad neutralizing antibodies capsid caused clinical testing comparable control group convalescent Corona coronavirus COVID-19 demonstrated disease dose-dependent manner Efficacy Evidence evidence of immunogenicity increase in Level macaque mice Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers no evidence of non-human primate non-human primates non-human primates (NHP) protection Protective reduction in respiratory rhesus macaques SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 single vaccination Vaccine vaccine administration vaccine group variants variants of concern variants of concern (VOCs) Viral Viral load Virus-like particle virus-like particles virus-like particles (VLP). VLP VOCs worldwide pandemic [DOI] 10.3389/fimmu.2022.857440 PMC 바로가기 [Article Type] Article